Eculizumab is an effective and safe treatment for refractory generalized myasthenia gravis

Takeaway

  • 88% of people with refractory generalized myasthenia gravis (gMG) had improved symptoms, whilst 57.3% had achieved minimal manifestation (MM) status after 130 weeks of eculizumab treatment.

Why this matters

    The study provides Class II evidence that eculizumab provides benefits and is safe to use in people with refractory gMG and supports the use in a previously difficult to treat population.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.